Cell Therapy Development for Ovarian Cancer
  • Home
  • Cell Therapy Development for Ovarian Cancer
Online Inquiry

Cell Therapy Development for Ovarian Cancer

Cell therapy for ovarian cancer represents one of the rapidly evolving frontiers in cancer treatment. Unlike traditional approaches such as surgery, radiation, and chemotherapy, cell therapy involves using living cells to combat cancer. Alfa Cytology possesses extensive expertise in ovarian cancer cell therapy research and is dedicated to consistently pioneering innovative cellular therapies.

Overview of Cell Therapy

Cell therapy is a treatment approach that leverages the individual's own cells to fight diseases, including ovarian cancer. This innovative technique is gaining traction as a leading-edge strategy for ovarian cancer treatment, primarily through immune cell therapies like chimeric antigen receptor T-cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy. These advanced therapies involve genetically altering or stimulating the body's immune cells, empowering them to accurately identify and attack ovarian cancer cells with exceptional precision.

General schematic for using DC vaccines and TIL-ACT for patients with ovarian cancer.Fig 1. General schematic for using DC vaccines and TIL-ACT for patients with ovarian cancer. (SARIVALASIS A, et al., 2021)

Our Services

Focusing on ovarian cancer cell therapy research, Alfa Cytology is dedicated to transforming and activating an individual's own cells through innovative immune cell therapies designed to more accurately identify and destroy ovarian cancer cells. Leveraging our extensive experience and cutting-edge technology, our company continually advances this dynamic field, striving to develop even more effective and beneficial cellular therapies.

Tumor-Infiltrating Lymphocytes (TILs)

TILs are used to extract T cells that have already infiltrated the tumor, expand and activate them in vitro, and then reinfuse them back into the individual to kill ovarian cancer cells.

Chimeric Antigen Receptor T-Cell (CAR-T)

Conducting CAR-T cell therapy typically involves genetically engineering T cells to express specific receptors that can efficiently recognize proteins present on ovarian cancer cells.

T-Cell Receptor (TCR)

TCRs are specialized proteins on T cells, a type of immune cell that enable these cells to recognize and bind specific antigens presented by other cells often signaling an immune response.

Natural Killer (NK) Cell Therapy

NK cell therapy is utilized to target and destroy ovarian cancer cells by enhancing or expanding a patient's own NK cells or using engineered NK cells from healthy donors.

CIK Cell Therapy

This research explores CIK cell therapy, which combines T cells and NK cell properties to target and eliminate cancer cells, offering a promising approach to cancer treatment.

Dendritic Cell (DC) Therapy

DC therapy is explored, which involves utilizing the body's own dendritic cells to enhance the immune response against cancer by processing and presenting antigens to T-cells.

Workflow of Cell Therapy

Cell Isolation

Our research team can separate specific cell types from a mixture or tissue. It's essential for studying particular cells in detail or for therapeutic applications.

Cell Culture and Activation

This involves growing cells under controlled conditions, typically outside their natural environment. Activation refers to stimulating cells to perform certain functions.

Cell Engineering

We can modification of cells to exhibit desired traits or functions. Techniques such as genetic modification are used to study cell behaviors or develop treatments.

Cell Expansion

This process aims at increasing the number of cells, often for research or therapeutic applications, ensuring a sufficient quantity of cells for practical use.

Cell Characterization

Our team can assess cell attributes like type, purity, and function.

Alfa Cytology is dedicated to the research of cell therapy for ovarian cancer, focusing on the development and optimization of immune cell therapies to enhance the precision and effectiveness of treatment. If you are interested in our research and related services, please feel free to contact us.

Reference

  1. SARIVALASIS A, MOROTTI M, MULVEY A, et al. Cell therapies in ovarian cancer [J]. Ther Adv Med Oncol, 2021, 13: 17588359211008399.

! For research use only.